1. Home
  2. ATCH vs CHRO Comparison

ATCH vs CHRO Comparison

Compare ATCH & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATCH
  • CHRO
  • Stock Information
  • Founded
  • ATCH 2022
  • CHRO 2002
  • Country
  • ATCH United States
  • CHRO United States
  • Employees
  • ATCH N/A
  • CHRO N/A
  • Industry
  • ATCH
  • CHRO
  • Sector
  • ATCH
  • CHRO
  • Exchange
  • ATCH Nasdaq
  • CHRO Nasdaq
  • Market Cap
  • ATCH 3.7M
  • CHRO 3.9M
  • IPO Year
  • ATCH N/A
  • CHRO 2024
  • Fundamental
  • Price
  • ATCH $0.17
  • CHRO $0.66
  • Analyst Decision
  • ATCH
  • CHRO Strong Buy
  • Analyst Count
  • ATCH 0
  • CHRO 1
  • Target Price
  • ATCH N/A
  • CHRO N/A
  • AVG Volume (30 Days)
  • ATCH 11.0M
  • CHRO 100.6K
  • Earning Date
  • ATCH 11-29-2024
  • CHRO 11-13-2024
  • Dividend Yield
  • ATCH N/A
  • CHRO N/A
  • EPS Growth
  • ATCH N/A
  • CHRO N/A
  • EPS
  • ATCH 0.04
  • CHRO N/A
  • Revenue
  • ATCH N/A
  • CHRO N/A
  • Revenue This Year
  • ATCH N/A
  • CHRO N/A
  • Revenue Next Year
  • ATCH N/A
  • CHRO N/A
  • P/E Ratio
  • ATCH $4.04
  • CHRO N/A
  • Revenue Growth
  • ATCH N/A
  • CHRO N/A
  • 52 Week Low
  • ATCH $0.12
  • CHRO $0.52
  • 52 Week High
  • ATCH $10.26
  • CHRO $6.00
  • Technical
  • Relative Strength Index (RSI)
  • ATCH 44.35
  • CHRO 48.22
  • Support Level
  • ATCH $0.17
  • CHRO $0.63
  • Resistance Level
  • ATCH $0.26
  • CHRO $0.69
  • Average True Range (ATR)
  • ATCH 0.04
  • CHRO 0.06
  • MACD
  • ATCH 0.00
  • CHRO 0.01
  • Stochastic Oscillator
  • ATCH 12.92
  • CHRO 52.55

About ATCH AtlasClear Holdings Inc. Common Stock

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

About CHRO Chromocell Therapeutics Corporation

Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.

Share on Social Networks: